Objective: To compare the effect of early and late cord clamping (LCC) on neonatal hematocrit at 2 and 18 h of life.Study Design: In this double-blind randomized trial, 64 healthy fullterm vaginally born neonates were randomly allocated to either early (30 s) or late (3 min) umbilical cord clamping. During the interval between delivery and cord clamping, the attendant held the neonate supine at the level of the introitus. Neonatal venous hematocrit was measured at 2 and 18 h of life.Result: Neonatal hematocrit at 2 h of life (61±4.9 vs 61.6±4.5%) and 18 h of life (56.9 ± 4.1 vs 56.2 ± 3.9%) was not significantly different between the two groups. This was also true for neonatal polycythemia (20 vs 23.5%). In the LCC group, placental residual blood volume (PRBV) was 39.5% lower and estimated neonatal blood volume (ENBV) was 7.1% higher than that in the early cord clamping (ECC) group (P<0.001).Conclusion: Late cord clamping does not lead to a significant difference in the hematocrit level of the neonate or neonatal polycythemia, but is associated with a significant increase in ENBV and a significant decrease in PRBV. Further trials should examine the effect of delaying cord clamping for a longer period of time or changing the position that the neonate is held in to determine whether these variations result in more clinically significant results.
Combined therapy with deferoxamine and deferiprone significantly decreases serum ferritin level. It has little side effect and is suggested for major beta-thalassemic patients as a suitable therapy.
Background: Primary dysmenorrhoea is a common, idiopathic, chronic pelvic pain syndrome, with unknown aetiology which about 50% of women with regular menstrual period suffer. This study was designed to determine the effect of vibration and heat on primary dysmenorrhea. Materials and Methods: In this clinical trial, 75 female students aged 18-22 years old were evaluated for two menstrual cycles. At the first cycle the participants received the routine pain-relief method (synthetic or herbal medicine and traditional remedies). At the second cycle for each participant combined vibration-heat device was applied for ten minutes during menstrual pain. The average of perceived leg pain, lumbar pain and abdominal pain scores at two cycles were determined. The data were analyzed based on Wilcoxon and T tests by using SPSS (v 16.0) for Windows. Results: The average of all perceived pain scores at two cycles were significantly different before pain relief and after both routine methods and using the device (p<0.001). Those were more significantly reduced after using the device in comparison of using routine methods (p<0.001). Conclusion: Since -vibration-heat‖ is an effective pain relief method, it can be used as a complementary alternative medicine in primary dysmenorrhea reduction.
Background: Iron extra load is an anticipated and lethal consequence of chronic blood transfusion in major beta-thalassemia patients; therefore it is necessary to use an efficient iron chelator drug to stimulate the evacuation of the surplus iron from the body. This trial was performed to compare myocardial and hepatic magnetic resonance imaging T2 (MRI T2*) results of beta-thalassemia patients treated by Deferasirox or combination of Deferoxamine and Deferiprone.
Material and Methods: In this clinical trial, 44 patients who were on combination therapy with Deferiprone and Deferoxamine and complied with the inclusion criteria were randomized to either case (Deferasirox) or control (combined therapy) groups. Twenty-two patients in the case group received Deferasirox. For 22 patients in the control group, prior treatment with Deferiprone and Deferoxamine was continued. Myocardial and hepatic MRI T2* results were assessed before and after the study. Moreover, serum ferritin level (SFL) was evaluated every 3 months.
Results: SFL at the start of the study did not differ significantly in two groups (2158.1± 1012.2 μg/L in the control group vs. 2145.5±1121.4 μg/L in the case group) (P=0.08). SFL at the end of the study did not differ significantly in two groups (2204.4±1143.5 μg/L in the control group vs. 2347.2±1236.6 μg/L in the case group), either (P=0.12). In each group, myocardial and hepatic MRI T2 at the start and at the end of the trial did not differ significantly (P>0.1).
Conclusion: Myocardial and hepatic MRI T2*results were better in the control (combination therapy) group than those in the case (Deferasirox) group. Major beta-thalassemia patients replied to combined treatment better than Deferasirox.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.